SUMMARY Although vasodilator drugs cause haemodynamic improvement at rest, their effect on the overall exercise response is uncertain. Nine patients with severe diuretic dependent cardiac failure were studied before and during upright bicycle exercise, after the double blind administration of equihypotensive doses of hydralazine (H) 75 mg, prazosin (Pr) 3 mg, and placebo (P1). The ventilatory response and oxygen uptake were monitored continuously. Cardiac output was measured during the third mtnute of steady state exercise by the CO2 rebreathing method.
Vasodilator drugs are effective in both short-and long-term treatment of patients with severe heart failure.1-3 Though their effects on resting haemodynamics are well defined, it is not yet clear whether they improve the exercise performance of such patients. Some reports have suggested an improvement in exercise capacity and haemodynamic reserves after the acute administration of a vasodilator drug,4 whereas others showed no change in maximal exercise capacity, but improved pump function at submaximal workloads.6
In the present study, we have compared the effects of the predominantly arteriolar vasodilator hydralazine with the arteriolar and venodilator agent prazosin on the cardiac output and ventilatory responses during maximal and steady state exercise and on the time over which such exercise can be tolerated.
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Patients and methods
Nine patients with chronic congestive heart failure and class II to III symptomatology (New York Heart Association criteria) were included in the study. Their ages ranged from 27 to 65 years (mean 47 years); seven were men and two were women. All were taking optimal doses of diuretics and digoxin which were continued in unchanged doses throughout the study. The patients' symptoms and weight were also unchanged for four weeks before the study. Heart 1   385 404 364   84  93  96  80  73  80  2-2  2-3  2-2  26  25  23  2  249 279 299  122  117  132  86  87  80  1-3  2 9  2-7  12  25  21  3   333 284 265   114  108  93  90  80  63  1*6  2 7  1*7  15  25  18  4  387 323 356  108 112  120   97  86  86  1 8  2-5  3-1  17  22  26   5  340 274 317  114 114  114  86  80  90  2-6  2 4  2-4  23  21  21  6  233 314 313  72  84  70  83  88  82  2 3  2-1  2 
Results

RESTING MEASUREMENTS
The effects of hydralazine and prazosin are compared with placebo for the resting patient seated on the bicycle ergometer (Table 1 and Fig.) . Cardiac index increased significantly after prazosin from 1.9±01 to 2-4±0-1l/min per m2 (p<Q005), but after hydralazine the increase did not achieve statistical significance. Systemic vascular resistance was reduced from 2217 ±271 to 1782 ±140 dynes s cm-5 after hydralazine (p < 0 05) and to 1461 ±214 dynes s cm-5 after prazosin (p < 0-01). The arteriovenous oxygen content difference decreased in both treatment groups (9-1 ±0 7 ml/ 100 ml versus hydralazine 7-1 ±0 4 ml/100 ml (p < 0 05) and prazosin 6 9 ±0 9 ml/100 ml (p < 0 005)).
PROGRESSIVE EXERCISE
The values in Table 2 represent the individual maxima attained on each treatment at the peak Although the predicted beneficial effects of both hydralazine and prazosin occurred at rest, there was no improvement in either maximal effort capacity or cardiac output during submaximal steady state exercise.
The failure of vasodilator drugs to improve the exercise performance of patients with cardiac failure may be the result of an interaction of several mechanisms. In the exercising patient with cardiac failure, the normal reduction of peripheral vascular resistance, and thus afterload, is restricted by increased sympathetic activity10 as well as an increased stiffness of the walls of the muscular arterioles.11 In the present study using the doses of drugs administered and the exercise loads studied, there was no augmentation of the fall in systemic vascular resistance towards normal levels by either agent.
The oxygen delivery to exercising muscles is an important factor limiting exercise capacity in both health and disease."2 In cardiac failure, the inadequate increase in cardiac output,13 and a limited ability of the resistance vessels in skeletal muscle to dilate,11 will decrease the oxygen delivery to the active muscle and reduce exercise capacity. Arteriolar vasodilator drugs act predominantly on visceral and skin vessels as well as dilating the arterioles in resting muscle, yet they would be expected to have no effect on the resistance vessels in the muscle of the exercising limb, which are already maximally dilated. Thus, any potentially beneficial increase in cardiac output may be diverted away from the exercising muscle, and could potentially decrease exercise capacity. 
